About Functional Brands, Inc. Common Stock
https://www.functionalbrandsinc.comThe company manufactures and distributes nutraceutical supplements in the U.S., covering categories such as pain, energy, prenatal, general health, bone & joint, gastro, immunity, cardiac, detox, brain & memory, sleep, and urinary. It also offers hemp-derived products including capsules, gummies and tinctures.
CEO
Eric Gripentrog
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Distribution
Sector Healthcare
Went public November 5, 2025
Full time employees 33
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0
Market Cap $1.52 M
52w High $8.00
52w Low $0.18
P/E -4.05
Volume 265.80K
Outstanding Shares 6.89M
About Functional Brands, Inc. Common Stock
https://www.functionalbrandsinc.comThe company manufactures and distributes nutraceutical supplements in the U.S., covering categories such as pain, energy, prenatal, general health, bone & joint, gastro, immunity, cardiac, detox, brain & memory, sleep, and urinary. It also offers hemp-derived products including capsules, gummies and tinctures.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $1.83M ▲ | $1.12M ▲ | $-226.06K ▼ | -12.34% ▼ | $-0.03 ▼ | $-56.53K ▼ |
| Q1-2025 | $1.59M ▼ | $898.87K ▼ | $-126.78K ▲ | -7.97% ▲ | $-0.02 ▲ | $66.42K ▲ |
| Q4-2024 | $1.68M ▲ | $1.13M ▲ | $-283.72K ▼ | -16.89% ▲ | $-0.04 ▼ | $-40.56K ▲ |
| Q3-2024 | $1.4M ▼ | $975.44K ▼ | $-282.11K ▼ | -20.21% ▼ | $-0.04 ▼ | $-101.75K ▼ |
| Q2-2024 | $1.77M | $977.34K | $-73.66K | -4.17% | $-0.01 | $64.51K |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $257.68K ▲ | $7.67M ▲ | $7.41M ▲ | $257.16K ▲ |
| Q1-2025 | $213.63K ▲ | $7.4M ▲ | $7.25M ▼ | $153.01K ▲ |
| Q4-2024 | $211.64K ▼ | $7.17M ▲ | $7.29M ▼ | $-118.58K ▲ |
| Q3-2024 | $246.9K | $7.09M | $7.34M | $-249.76K |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-226.06K ▼ | $471.76K ▲ | $0 | $-427.71K ▼ | $44.05K ▲ | $471.76K ▲ |
| Q1-2025 | $-126.78K ▲ | $175.99K ▲ | $0 | $-174K ▼ | $1.99K ▲ | $175.99K ▲ |
| Q4-2024 | $-283.72K ▼ | $59.44K ▲ | $0 ▲ | $-94.7K ▲ | $-35.26K ▲ | $59.44K ▲ |
| Q3-2024 | $-282.11K ▼ | $-61.29K ▼ | $-3.76K ▼ | $-134.82K ▼ | $-199.88K ▼ | $-63.17K ▼ |
| Q2-2024 | $-73.66K | $24.27K | $0 | $40.92K | $67.07K | $24.27K |
CEO
Eric Gripentrog
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Medical - Distribution
Sector Healthcare
Went public November 5, 2025
Full time employees 33
Ratings Snapshot
Rating : D+
Discounted Cash Flow 1
Return On Equity 1
Return On Assets 1
Debt To Equity 1
Price To Earnings 1
Price To Book 1
Overall Score 1
Price Target
Target High $0
Target Low $0
Target Median $0
Target Consensus $0